Published in Hepatology on June 06, 2012
Interactions between the intestinal microbiome and liver diseases. Gastroenterology (2014) 1.92
Plasma lysophosphatidylcholine levels are reduced in obesity and type 2 diabetes. PLoS One (2012) 1.28
The metabolomic window into hepatobiliary disease. J Hepatol (2013) 1.24
Role of white adipose lipolysis in the development of NASH induced by methionine- and choline-deficient diet. Biochim Biophys Acta (2014) 1.03
Metabolomics identifies an inflammatory cascade involved in dioxin- and diet-induced steatohepatitis. Cell Metab (2012) 1.01
Role of fibroblast growth factor 21 in the early stage of NASH induced by methionine- and choline-deficient diet. Biochim Biophys Acta (2015) 0.95
Altered Bile Acid Metabolome in Patients with Nonalcoholic Steatohepatitis. Dig Dis Sci (2015) 0.92
Metabolomics reveals an essential role for peroxisome proliferator-activated receptor α in bile acid homeostasis. J Lipid Res (2012) 0.91
Recognition of lysophosphatidylcholine by type II NKT cells and protection from an inflammatory liver disease. J Immunol (2014) 0.88
Circulating lysophosphatidylcholines are markers of a metabolically benign nonalcoholic fatty liver. Diabetes Care (2013) 0.88
TGF-β-SMAD3 signaling mediates hepatic bile acid and phospholipid metabolism following lithocholic acid-induced liver injury. J Lipid Res (2012) 0.87
Adipocyte-specific disruption of fat-specific protein 27 causes hepatosteatosis and insulin resistance in high-fat diet-fed mice. J Biol Chem (2014) 0.85
Chronic exposure to rifaximin causes hepatic steatosis in pregnane X receptor-humanized mice. Toxicol Sci (2012) 0.85
Metabolomic profiles of hepatocellular carcinoma in a European prospective cohort. BMC Med (2015) 0.85
A weighted relative difference accumulation algorithm for dynamic metabolomics data: long-term elevated bile acids are risk factors for hepatocellular carcinoma. Sci Rep (2015) 0.84
Strategies, models and biomarkers in experimental non-alcoholic fatty liver disease research. Prog Lipid Res (2015) 0.84
Bile acids permeabilize the blood brain barrier after bile duct ligation in rats via Rac1-dependent mechanisms. Dig Liver Dis (2014) 0.84
Absence of Elovl6 attenuates steatohepatitis but promotes gallstone formation in a lithogenic diet-fed Ldlr(-/-) mouse model. Sci Rep (2015) 0.81
Lipid zonation and phospholipid remodeling in non-alcoholic fatty liver disease. Hepatology (2016) 0.80
Innate immune signaling and gut-liver interactions in non-alcoholic fatty liver disease. Hepatobiliary Surg Nutr (2014) 0.80
Metabolomics Reveals that Aryl Hydrocarbon Receptor Activation by Environmental Chemicals Induces Systemic Metabolic Dysfunction in Mice. Environ Sci Technol (2015) 0.80
Experimental Periodontitis Results in Prediabetes and Metabolic Alterations in Brain, Liver and Heart: Global Untargeted Metabolomic Analyses. J Oral Biol (Northborough) (2016) 0.78
Hepatic and serum lipid signatures specific to nonalcoholic steatohepatitis in murine models. Sci Rep (2016) 0.76
A targeted analysis reveals relevant shifts in the methylation and transcription of genes responsible for bile acid homeostasis and drug metabolism in non-alcoholic fatty liver disease. BMC Genomics (2016) 0.76
Systems level metabolic phenotype of methotrexate administration in the context of non-alcoholic steatohepatitis in the rat. Toxicol Sci (2014) 0.76
Simple steatosis sensitizes cholestatic rats to liver injury and dysregulates bile salt synthesis and transport. Sci Rep (2016) 0.76
A model of in vitro UDP-glucuronosyltransferase inhibition by bile acids predicts possible metabolic disorders. J Lipid Res (2013) 0.76
Muscle and liver-specific alterations in lipid and acylcarnitine metabolism after a single bout of exercise in mice. Sci Rep (2016) 0.75
Reply:. Hepatology (2012) 0.75
Bile acids in nonalcoholic steatohepatitis: inserting nuclear receptors into the circle. Hepatology (2012) 0.75
Hepatic transcriptomic alterations for N,N-dimethyl-p-toluidine (DMPT) and p-toluidine after 5-day exposure in rats. Arch Toxicol (2016) 0.75
Gene-metabolite network analysis in different nonalcoholic fatty liver disease phenotypes. Exp Mol Med (2017) 0.75
Differential proteomics profiling identifies LDPs and biological functions in high-fat diet-induced fatty livers. J Lipid Res (2017) 0.75
Choline Deficiency Causes Colonic Type II Natural Killer T (NKT) Cell Loss and Alleviates Murine Colitis under Type I NKT Cell Deficiency. PLoS One (2017) 0.75
Metabolism dysregulation induces a specific lipid signature of nonalcoholic steatohepatitis in patients. Sci Rep (2017) 0.75
Remote Sensing between Liver and Intestine: Importance of Microbial Metabolites. Curr Pharmacol Rep (2017) 0.75
Growth arrest and DNA damage-inducible 45α protects against nonalcoholic steatohepatitis induced by methionine- and choline-deficient diet. Biochim Biophys Acta (2017) 0.75
Obesity, adipokines, and C-peptide are associated with distinct plasma phospholipid profiles in adult males, an untargeted lipidomic approach. Sci Rep (2017) 0.75
Effect of Liver Disease on Hepatic Transporter Expression and Function. J Pharm Sci (2017) 0.75
Molecular mechanisms of nonalcoholic fatty liver disease: Potential role for 12-lipoxygenase. J Diabetes Complications (2017) 0.75
Mitochondrial autophagy is an HIF-1-dependent adaptive metabolic response to hypoxia. J Biol Chem (2008) 7.71
C/EBPalpha induces adipogenesis through PPARgamma: a unified pathway. Genes Dev (2002) 6.46
Macrophage PPAR gamma is required for normal skeletal muscle and hepatic insulin sensitivity and full antidiabetic effects of thiazolidinediones. J Clin Invest (2007) 4.86
Regulation of hepatic fasting response by PPARgamma coactivator-1alpha (PGC-1): requirement for hepatocyte nuclear factor 4alpha in gluconeogenesis. Proc Natl Acad Sci U S A (2003) 4.34
Role of aryl hydrocarbon receptor-mediated induction of the CYP1 enzymes in environmental toxicity and cancer. J Biol Chem (2004) 4.10
Liver peroxisome proliferator-activated receptor gamma contributes to hepatic steatosis, triglyceride clearance, and regulation of body fat mass. J Biol Chem (2003) 3.90
Differential regulation of bile acid homeostasis by the farnesoid X receptor in liver and intestine. J Lipid Res (2007) 3.84
Activation of the nuclear receptor FXR improves hyperglycemia and hyperlipidemia in diabetic mice. Proc Natl Acad Sci U S A (2006) 3.77
Loss of ARNT/HIF1beta mediates altered gene expression and pancreatic-islet dysfunction in human type 2 diabetes. Cell (2005) 3.52
International Union of Pharmacology. LXI. Peroxisome proliferator-activated receptors. Pharmacol Rev (2006) 3.48
PPARdelta regulates glucose metabolism and insulin sensitivity. Proc Natl Acad Sci U S A (2006) 3.29
Adipocyte-specific gene expression and adipogenic steatosis in the mouse liver due to peroxisome proliferator-activated receptor gamma1 (PPARgamma1) overexpression. J Biol Chem (2002) 3.24
Liver-specific disruption of PPARgamma in leptin-deficient mice improves fatty liver but aggravates diabetic phenotypes. J Clin Invest (2003) 3.09
Conditional disruption of the peroxisome proliferator-activated receptor gamma gene in mice results in lowered expression of ABCA1, ABCG1, and apoE in macrophages and reduced cholesterol efflux. Mol Cell Biol (2002) 3.02
Muscle-specific PPARgamma-deficient mice develop increased adiposity and insulin resistance but respond to thiazolidinediones. J Clin Invest (2003) 2.87
Role of the hepatocyte nuclear factor 4alpha in control of the pregnane X receptor during fetal liver development. Hepatology (2003) 2.70
Hepatic steatosis in leptin-deficient mice is promoted by the PPARgamma target gene Fsp27. Cell Metab (2008) 2.57
Collecting duct-specific deletion of peroxisome proliferator-activated receptor gamma blocks thiazolidinedione-induced fluid retention. Proc Natl Acad Sci U S A (2005) 2.56
Modification of ocular defects in mouse developmental glaucoma models by tyrosinase. Science (2003) 2.41
PPARgamma and PPARdelta negatively regulate specific subsets of lipopolysaccharide and IFN-gamma target genes in macrophages. Proc Natl Acad Sci U S A (2003) 2.40
Peroxisome proliferator-activated receptor alpha protects against alcohol-induced liver damage. Hepatology (2004) 2.40
The farnesoid X receptor modulates adiposity and peripheral insulin sensitivity in mice. J Biol Chem (2006) 2.38
Thermogenic activation induces FGF21 expression and release in brown adipose tissue. J Biol Chem (2011) 2.35
Hepatic FGF21 expression is induced at birth via PPARalpha in response to milk intake and contributes to thermogenic activation of neonatal brown fat. Cell Metab (2010) 2.30
Peroxisome proliferator-activated receptor-gamma coactivator 1alpha (PGC-1alpha) regulates triglyceride metabolism by activation of the nuclear receptor FXR. Genes Dev (2004) 2.30
Radiation metabolomics. 1. Identification of minimally invasive urine biomarkers for gamma-radiation exposure in mice. Radiat Res (2008) 2.27
Plasticity and expanding complexity of the hepatic transcription factor network during liver development. Genes Dev (2006) 2.23
Spontaneous hepatocarcinogenesis in farnesoid X receptor-null mice. Carcinogenesis (2006) 2.18
C/EBPalpha regulates hepatic transcription of hepcidin, an antimicrobial peptide and regulator of iron metabolism. Cross-talk between C/EBP pathway and iron metabolism. J Biol Chem (2002) 2.16
Intestinal hypoxia-inducible transcription factors are essential for iron absorption following iron deficiency. Cell Metab (2009) 2.09
The role of peroxisome proliferator-activated receptors in carcinogenesis and chemoprevention. Nat Rev Cancer (2012) 2.06
Complementary roles of farnesoid X receptor, pregnane X receptor, and constitutive androstane receptor in protection against bile acid toxicity. J Biol Chem (2003) 2.04
A natural product that lowers cholesterol as an antagonist ligand for FXR. Science (2002) 1.99
The pollutant diethylhexyl phthalate regulates hepatic energy metabolism via species-specific PPARalpha-dependent mechanisms. Environ Health Perspect (2010) 1.98
The farnesoid X-receptor is an essential regulator of cholesterol homeostasis. J Biol Chem (2002) 1.97
Peroxisome proliferator-activated receptor-delta attenuates colon carcinogenesis. Nat Med (2004) 1.92
A chemical-genetic approach to study G protein regulation of beta cell function in vivo. Proc Natl Acad Sci U S A (2009) 1.90
Peroxisome proliferator-activated receptor alpha regulates a microRNA-mediated signaling cascade responsible for hepatocellular proliferation. Mol Cell Biol (2007) 1.90
APC-dependent suppression of colon carcinogenesis by PPARgamma. Proc Natl Acad Sci U S A (2002) 1.89
Regeneration of serotonin from 5-methoxytryptamine by polymorphic human CYP2D6. Pharmacogenetics (2003) 1.85
Hypotension, lipodystrophy, and insulin resistance in generalized PPARgamma-deficient mice rescued from embryonic lethality. J Clin Invest (2007) 1.85
Role of nuclear bile acid receptor, FXR, in adaptive ABC transporter regulation by cholic and ursodeoxycholic acid in mouse liver, kidney and intestine. J Hepatol (2003) 1.85
The farnesoid X receptor modulates hepatic carbohydrate metabolism during the fasting-refeeding transition. J Biol Chem (2005) 1.85
Microbiome remodelling leads to inhibition of intestinal farnesoid X receptor signalling and decreased obesity. Nat Commun (2013) 1.84
The orphan nuclear receptor HNF4alpha determines PXR- and CAR-mediated xenobiotic induction of CYP3A4. Nat Med (2003) 1.81
Role of farnesoid X receptor in determining hepatic ABC transporter expression and liver injury in bile duct-ligated mice. Gastroenterology (2003) 1.79
LC-MS-based metabolomics in drug metabolism. Drug Metab Rev (2007) 1.79
Hypoxia-inducible factor directs POMC gene to mediate hypothalamic glucose sensing and energy balance regulation. PLoS Biol (2011) 1.76
Breaking tolerance to the natural human liver autoantigen cytochrome P450 2D6 by virus infection. J Exp Med (2008) 1.76
Defective brain development in mice lacking the Hif-1alpha gene in neural cells. Mol Cell Biol (2003) 1.75
Farnesoid X receptor deficiency improves glucose homeostasis in mouse models of obesity. Diabetes (2011) 1.73
The HNF-1 target collectrin controls insulin exocytosis by SNARE complex formation. Cell Metab (2005) 1.72
Peroxisome proliferator-activated receptor-alpha and liver cancer: where do we stand? J Mol Med (Berl) (2005) 1.71
Oral benzo[a]pyrene in Cyp1 knockout mouse lines: CYP1A1 important in detoxication, CYP1B1 metabolism required for immune damage independent of total-body burden and clearance rate. Mol Pharmacol (2005) 1.71
Hypoxia-inducible factor-1alpha regulates beta cell function in mouse and human islets. J Clin Invest (2010) 1.70
Role of CYP1B1 in glaucoma. Annu Rev Pharmacol Toxicol (2008) 1.69
PPARgamma in the endothelium regulates metabolic responses to high-fat diet in mice. J Clin Invest (2008) 1.68
Aberrant lipid metabolism in hepatocellular carcinoma revealed by plasma metabolomics and lipid profiling. Cancer Res (2011) 1.67
Human PXR modulates hepatotoxicity associated with rifampicin and isoniazid co-therapy. Nat Med (2013) 1.67
Metabolomics reveals that hepatic stearoyl-CoA desaturase 1 downregulation exacerbates inflammation and acute colitis. Cell Metab (2008) 1.67
Vascular PPARgamma controls circadian variation in blood pressure and heart rate through Bmal1. Cell Metab (2008) 1.65
The role of peroxisome proliferator-activated receptor-beta/delta in epithelial cell growth and differentiation. Cell Signal (2005) 1.64
Polymorphic cytochrome P450 2D6: humanized mouse model and endogenous substrates. Drug Metab Rev (2004) 1.63
PPARalpha protects proximal tubular cells from acute fatty acid toxicity. J Am Soc Nephrol (2007) 1.62
Pregnane X receptor activation ameliorates DSS-induced inflammatory bowel disease via inhibition of NF-kappaB target gene expression. Am J Physiol Gastrointest Liver Physiol (2006) 1.62
Farnesoid X receptor deficiency in mice leads to increased intestinal epithelial cell proliferation and tumor development. J Pharmacol Exp Ther (2008) 1.62
UPLC-ESI-TOFMS-based metabolomics and gene expression dynamics inspector self-organizing metabolomic maps as tools for understanding the cellular response to ionizing radiation. Anal Chem (2008) 1.61
Liver receptor homologue-1 mediates species- and cell line-specific bile acid-dependent negative feedback regulation of the apical sodium-dependent bile acid transporter. J Biol Chem (2002) 1.60
Targeted elimination of peroxisome proliferator-activated receptor gamma in beta cells leads to abnormalities in islet mass without compromising glucose homeostasis. Mol Cell Biol (2003) 1.60
Enzymatic mechanisms of ethanol oxidation in the brain. Alcohol Clin Exp Res (2006) 1.59
Radiation metabolomics. 2. Dose- and time-dependent urinary excretion of deaminated purines and pyrimidines after sublethal gamma-radiation exposure in mice. Radiat Res (2009) 1.59
Hypoxia-inducible factor augments experimental colitis through an MIF-dependent inflammatory signaling cascade. Gastroenterology (2008) 1.57
Disruption of hypoxia-inducible factor 1 in adipocytes improves insulin sensitivity and decreases adiposity in high-fat diet-fed mice. Diabetes (2011) 1.56
Intestinal farnesoid X receptor signaling promotes nonalcoholic fatty liver disease. J Clin Invest (2014) 1.55
PPARalpha activation is essential for HCV core protein-induced hepatic steatosis and hepatocellular carcinoma in mice. J Clin Invest (2008) 1.55
PPARgamma in endothelial cells influences high fat diet-induced hypertension. Am J Hypertens (2005) 1.55
Farnesoid X receptor agonists suppress hepatic apolipoprotein CIII expression. Gastroenterology (2003) 1.54
The toxicology of ligands for peroxisome proliferator-activated receptors (PPAR). Toxicol Sci (2005) 1.54
Role of CYP2E1 in diethylnitrosamine-induced hepatocarcinogenesis in vivo. Cancer Res (2007) 1.54
Hepatocyte nuclear factor-4alpha is essential for glucose-stimulated insulin secretion by pancreatic beta-cells. J Biol Chem (2005) 1.54
Role of peroxisome-proliferator-activated receptor beta/delta (PPARbeta/delta) in gastrointestinal tract function and disease. Clin Sci (Lond) (2008) 1.53
Alterations in skin and stratified epithelia by constitutively activated PPARalpha. J Invest Dermatol (2006) 1.53